Coherus Oncology (CHRS) Tax Provisions (2019 - 2023)

Coherus Oncology (CHRS) posted Tax Provisions of -$380000.0 for Q3 2023, down 136.12% sequentially from $1.1 million in Q4 2020.

Coherus Oncology (CHRS) Tax Provisions (2019 - 2023) Analysis & Trends

Coherus Oncology has reported Tax Provisions for 3 years, with the latest figure at -$380000.0 in Q3 2023.

Quarterly Tax Provisions changed N/A year-over-year to -$380000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$380000.0 (changed N/A YoY) and the FY2024 annual result came in at $116000.0, up 130.53% from the prior year.
Tax Provisions eased to -$380000.0 in Q3 2023 per CHRS's latest filing, from $1.1 million in the prior quarter.
Over five years, Tax Provisions peaked at $2.0 million in Q4 2019 and troughed at -$380000.0 in Q3 2023.
A 3-year average of $741625.0 and a median of $866500.0 in 2019 frame the typical range for Tax Provisions.
The widest YoY moves for Tax Provisions: up 2437.25% in 2020, down 77.12% in 2020.
Over 3 years, Tax Provisions stood at $2.0 million in 2019, then slumped by 47.4% to $1.1 million in 2020, then plunged by 136.12% to -$380000.0 in 2023.
According to Business Quant data, Tax Provisions over the past three periods registered -$380000.0, $1.1 million, and $183000.0 for Q3 2023, Q4 2020, and Q3 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Coherus Oncology	221.39 Mn	116.08 Mn	10.07 Mn	-

Download Data